Purinergic Signaling in Mast Cell Degranulation and Asthma

Mast cells are responsible for the majority of allergic conditions. It was originally thought that almost all allergic events were mediated directly only via the high-affinity immunoglobulin E receptors. However, recent evidence showed that many other receptors, such as G protein-coupled receptors a...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 8; p. 947
Main Authors Gao, Zhan-Guo, Jacobson, Kenneth A
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 22.12.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Mast cells are responsible for the majority of allergic conditions. It was originally thought that almost all allergic events were mediated directly only via the high-affinity immunoglobulin E receptors. However, recent evidence showed that many other receptors, such as G protein-coupled receptors and ligand-gated ion channels, are also directly involved in mast cell degranulation, the release of inflammatory mediators such as histamine, serine proteases, leukotrienes, heparin, and serotonin. These mediators are responsible for the symptoms in allergic conditions such as allergic asthma. In recent years, it has been realized that purinergic signaling, induced via the activation of G protein-coupled adenosine receptors and P2Y nucleotide receptors, as well as by ATP-gated P2X receptors, plays a significant role in mast cell degranulation. Both adenosine and ATP can induce degranulation and bronchoconstriction on their own and synergistically with allergens. All three classes of receptors, adenosine, P2X and P2Y are involved in tracheal mucus secretion. This review will summarize the currently available knowledge on the role of purinergic signaling in mast cell degranulation and its most relevant disease, asthma.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Vsevolod V. Gurevich, Vanderbilt University, United States
Reviewed by: Kempuraj Duraisamy, University of Missouri, United States; Silvia Bulfone-Paus, University of Manchester, United Kingdom; Vanesa Esteban, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Spain
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2017.00947